EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas.

ABSTRACT:

Context

Approximately 10% to 20% of prolactinomas are resistant to dopamine agonist therapy. The ErbB signaling pathway may drive aggressive prolactinoma behavior.

Objective

We evaluated lapatinib, an ErbB1-epidermal growth factor receptor (EGFR)/ErbB2 or human EGFR2 (HER2) tyrosine kinase inhibitor (TKI), in aggressive prolactinomas.

Design

A prospective, phase 2a multicenter trial was conducted.

Setting

This study took place at a tertiary referral pituitary center.

Patients

Study participants included adults with aggressive prolactinomas showing continued tumor growth despite maximally tolerated dopamine agonist therapy.

Intervention

Intervention included oral lapatinib 1250 mg/day for 6 months.

Main outcome measures

The primary end point

SUBMITTER: Cooper O 

PROVIDER: S-EPMC7823257 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature